Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935137 | 0.98 | MEN1 (0.38) | MEN1KMT2AMAPTCCNB2CDK1 | |
| SCHEMBL6236362 | 0.91 | MEN1 (0.36) | MEN1KMT2AMAPTCCNB2CDK1 | |
| SCHEMBL9451016 | 0.87 | MEN1 (0.44) | MEN1KMT2AMAPTCCNB2CDK1 | |
| SCHEMBL9912110 | 0.85 | ALDH1A1 (0.44) | MEN1KMT2AMAPTCCNB2CDK1 | |
| SCHEMBL10932117 | 0.79 | MEN1 (0.63) | MEN1KMT2AMAPTCYP2C19CYP19A1 | |
| SCHEMBL9636744 | 0.76 | SMN1; SMN2 (0.54) | MEN1KMT2AMAPTCYP2C19CYP19A1 | |
| SCHEMBL8804519 | 0.76 | TAAR1 (0.43) | KMT2ACYP2C19ALDH1A1TDP1KDM4E | |
| SCHEMBL9451018 | 0.76 | MEN1 (0.41) | MEN1KMT2AMAPTCCNB2CDK1 | |
| SCHEMBL19265379 | 0.75 | CCNB2 (0.31) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL6809631 | 0.75 | MAPK1 (0.50) | MEN1KMT2ACCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108976216-B | Preparation method of prucalopride | 江苏工程职业技术学院 | 2021-02-12 | — | — | CN | claimed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| CN-114746434-B | Antibiotic compounds | 莱顿大学 | 2025-02-21 | — | — | CN | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| EP-4034547-B9 | ANTIBIOTIC COMPOUNDS | UNIV LEIDEN (NL) | 2024-09-04 | — | — | EP | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| EP-4034547-B1 | ANTIBIOTIC COMPOUNDS | UNIV LEIDEN (NL) | 2024-05-22 | — | — | EP | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-115521233-B | ROR gamma agonist and application thereof in preparing medicament for treating tumor diseases and promoting Type17 cell differentiation | 复旦大学 | 2024-02-09 | — | — | CN | disclosed |
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmaceuticals (CN) | 2024-01-18 | — | — | US | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| US-6667342-B1 | Elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2003-12-23 | — | — | US | disclosed |
| EP-1064274-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEDICAMENTS | AstraZeneca AB (SE) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047508-A1 | BENZENESULFONAMIDE-DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 1999-09-23 | — | — | WO | disclosed |
| US-4977272-A | Radiation absorbers | THE STANDARD OIL COMPANY (US) | 1990-12-11 | — | — | US | disclosed |
| US-4868061-A | ADDITION POLYMERS, ULTRAVIOLET RADIATION STABILIZERS | THE STANDARD OIL COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4740611-A | N,N'-disubstituted ureas | THE STANDARD OIL COMPANY (US) | 1988-04-26 | — | — | US | disclosed |
| US-4705864-A | Aryl oxime derivatives of hydantoins | THE STANDARD OIL COMPANY (US) | 1987-11-10 | — | — | US | disclosed |
| US-4309553-A | HYPOLIPIDEMIC, ANTIATHEROSCLEROTIC | AMERICAN CYANAMID COMPANY (US) | 1982-01-05 | — | — | US | disclosed |
| US-4273785-A | ANTILIPEMIC AGENTS, ANTIATHEROSCEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | FLI1, MCL1, SP1 | MEN1 3037/4885KMT2A 2056/4885MAPT 4351/4885 |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | MEN1 3627/4885KMT2A 512/4885MAPT 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.